Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2020 Mar;147:102893. doi: 10.1016/j.critrevonc.2020.102893. Epub 2020 Jan 30.

The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer.

Author information

1
Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, 200072 China.
2
Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, 200072 China. Electronic address: doctorzangys@163.com.

Abstract

The present study aimed to evaluate the effect of liver metastases on the efficacy from the combination of PD-1/PD-L1 inhibitor with chemotherapy as first-line treatment in lung cancer using the meta-analysis. A total of 8 randomized controlled trials (RCTs) were included. In patients without liver metastases, PD-1/PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 40% and risk of death by 29% (HR = 0.60; 95%CI,0.55- 0.65 and HR = 0.71;95%CI,0.58-0.90 respectively). In patients with liver metastases, PD-1/PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 31% and risk of death by 21% (HR = 0.69;95%CI,0.58-0.81; and HR = 0.79; 95%CI,0.62-0.80, respectively). The pooled ratios of PFS-HRs and OS- HRs reported in lung cancer patients with liver metastases versus those without liver metastases were 1.11 (95%CI, 0.92-1.34) and 1.03 (95%CI, 0.80-1.35), respectively, suggesting that lung cancer patients with and without liver metastases could obtain comparable efficacy.

KEYWORDS:

Chemotherapy; Immunotherapy; Liver metastases; Lung cancer; PD-1/PD-L1 inhibitor

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center